Ness Therapeutics

What Ness Therapeutics does

Ness Therapeutics Inc. is a privately held Canadian biotechnology company headquartered in Toronto that is developing a pipeline of host-directed, virus-agnostic prophylactic therapeutics for respiratory and other viral infections. Its lead program, N001, is a self-administered intranasal nasal spray built on a recombinant protein platform designed to activate innate antiviral defenses at the upper airway — the point of entry for respiratory viruses — rather than targeting any specific pathogen. The mechanism is intended to provide broad protection against known and emerging respiratory threats and to fill what the company characterizes as an unaddressed first-contact gap left by vaccines, antivirals, and monoclonal antibody therapies, which are pathogen-specific and largely reactive. Supporting evidence cited by the company includes a household randomized clinical trial of 1,172 participants across 341 households showing a transmission signal with lower viral burden in exposed contacts, alongside preclinical data across multiple respiratory viral models and human lung tissue studies.

The broader pipeline extends the host-directed platform into non-respiratory viral prophylaxis (N003), enterovirus prophylaxis (N004), and an early-stage oncology program (N007) exploring intranasal delivery as a tumor-priming agent in combination with checkpoint blockade. The business model is presently non-commercial: the company is pre-revenue and in IND/CTA-enabling development, sustained by non-dilutive Government of Canada funding and a co-development partnership with the National Research Council of Canada. Future commercialization, if N001 reaches approval, is envisioned through pharmaceutical sales, licensing, or partnership with larger manufacturers, with target end-markets spanning general consumers, healthcare settings, and government/defense stockpiling. The company employs 1-10 people and was founded by Eleanor N. Fish (Founder & President/Scientific Advisor) and Ramtin Rahbar (Co-Founder & Chief Technical Officer).

Name

Ness Therapeutics

Legal name

Ness Therapeutics Inc.

Website

https://nesstherapeuticsinc.com

Company type

Private

Operating status

Operating

Headcount range

1–10 employees

Short description

Ness Therapeutics Inc. is a Toronto-based pre-revenue biotech developing N001, a host-directed, virus-agnostic intranasal nasal spray designed to prevent respiratory virus infection by activating innate antiviral defenses at the upper airway, targeting consumers, healthcare providers, and government/defense buyers.

Ownership category

akta.pro rank

Product category

Respiratory Prophylactics

NAICS

Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)

akta.pro primary industry

Infectious Disease Specialty Pharmaceuticals (Non-vaccine) (HLAIACAM)

akta.pro secondary industries

Vaccine Delivery & Administration Systems (needle-free, microneedle patches, intranasal/oral) (HLAAAEAF), Pandemic Preparedness & Rapid-Response Vaccines (HLAIAEAF)

Keywords

• Intranasal prophylaxis
• Respiratory virus prevention
• Host-directed antivirals
• Biopharmaceutical development
• Innate immunity therapeutics

Headquarters

HQ city

Toronto

HQ country

Canada

HQ region

North America

Offices1 record

Markets served

GTM type

B2B and B2C

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales

Revenue model

1. N001 Commercialization: Ness Therapeutics is a pre-revenue biotech company developing N001, an intranasal prophylactic for respiratory virus protection. The company is in IND/CTA-enabling stage (as of 2025-2026). Revenue model will likely involve pharmaceutical product sales upon regulatory approval, potentially through direct commercialization or licensing/partnership arrangements with larger pharmaceutical companies.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels5 records

Core offering

Ness Therapeutics is developing N001, a self-administered intranasal prophylactic biologic designed to activate innate antiviral defenses directly at the upper airway. The recombinant protein-based nasal spray is host-directed and virus-agnostic, intended to prevent respiratory virus infection and enable early post-exposure use across known and emerging viral threats. The platform extends to additional pipeline programs (N003, N004, N007) targeting non-respiratory viral prophylaxis, enteroviruses, and oncology applications.

Product overview

Ness Therapeutics Inc. is a biotechnology company developing a focused pipeline of host-directed, virus-agnostic prophylactics. The core product is N001, an intranasal prophylactic for respiratory virus protection, which serves as the foundation of the platform. The pipeline includes additional programs: N003 for non-respiratory viral protection, N004 for enterovirus prophylaxis, and N007 for oncology applications. The company's approach focuses on activating the body's innate antiviral defenses at the point of entry rather than targeting specific pathogens.

Differentiator

Problem solved

Functional benefit

Brands

• N001: Lead program - a self-administered intranasal prophylactic for respiratory virus protection, acting at the upper airway with host-directed, virus-agnostic approach
• N003
• N004
• N007

Products and services

• N001 N001 is a self-administered intranasal prophylactic designed to activate innate antiviral defenses at the upper airway for prevention and early post-exposure use against known and emerging respiratory virus threats. It is host-directed and virus-agnostic, administered directly to the upper airway as a nasal spray, intended for consumers, healthcare workers, and government/defense populations.
• N003 N003 is a non-respiratory virus prophylaxis program exploring host-directed protection beyond the respiratory tract, with route of administration to be determined.
• N004 N004 is an enterovirus prophylaxis program evaluating targeted approaches for enterovirus infections, with route of administration to be determined.
• N007 N007 is an oncology program exploring early-stage host-directed immune activation, administered intranasally as a tumor-priming agent in combination with checkpoint blockade.

Quantifiable outcome

• Lower viral burden observed in exposed contacts in household randomized clinical trial (1,172 participants across 341 households)
• +3 more outcomes

Segments4 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Four partnerships are on record, tiered core and minor.

• National Research Council of Canada (NRC)coreStrategic or Co-development PartnerNess Therapeutics is partnered with the National Research Council of Canada in support of N001's development program. The NRC partnership provides technical development expertise and infrastructure for the Canadian biotech company's respiratory prophylactic program.
• European Government StakeholdersminorStrategic or Co-development PartnerDiscussions with representatives from multiple European jurisdictions including France, Italy (Lombardy), Switzerland (cantons of Neuchâtel and Vaud), Germany (Berlin and Mainz) regarding international collaboration opportunities, R&D expansion, and potential partnership for Ness Therapeutics' advancing clinical-stage program.
• Nordic Collaborators (Norway)minorStrategic or Co-development PartnerNorwegian representatives expressed specific interest in working with Ness Therapeutics on defense applications of N001, reflecting the program's relevance to high-readiness and frontline environments requiring deployable, host-directed prophylaxis.
• Biopôle (Lausanne, Switzerland)minorStrategic or Co-development PartnerBiopôle is one of Europe's largest life sciences campuses in Switzerland's Health Valley, home to 180+ companies and 3,500+ people. The ecosystem offers collaboration opportunities, funding support, mentoring, talent connectivity, and investor access relevant to Ness Therapeutics' European partnership strategy.

Scale indicators5 records

Recent moves5 records

Expansion highlights5 records

Broad incumbents

• Atea Pharmaceuticals: Atea develops oral direct-acting antivirals for RNA viruses including respiratory pathogens. A broader antiviral therapeutics incumbent whose post-exposure oral treatment positioning overlaps with N001's post-exposure prophylaxis use case.
• Arcturus Therapeutics: Arcturus develops mRNA-based vaccines and therapeutics including for respiratory viruses. A broad incumbent in respiratory virus vaccine development competing for the same pandemic preparedness procurement budgets Ness targets.
• Vir Biotechnology: Vir Biotechnology is a clinical-stage infectious disease company developing antibody-based and small-molecule antivirals for respiratory and other viral diseases. Larger incumbent operating broadly in respiratory antiviral therapeutics, overlapping with N001's intended indication space.
• Pfizer: Pfizer is the largest respiratory virus vaccine and antiviral franchise holder (Comirnaty, Paxlovid). The dominant incumbent Ness explicitly positions N001 against, and the most likely strategic acquirer/licensing partner.
• Moderna: Moderna is the leading mRNA vaccine company with respiratory virus franchises (COVID-19, RSV, flu combination programs). A broad incumbent whose pathogen-specific respiratory virus products define the competitive landscape N001 is positioned against.

Emerging players

• BioAegis Therapeutics: BioAegis develops host-directed, recombinant human plasma gelsolin therapies for infectious and inflammatory diseases. Comparable early-stage host-directed therapeutic strategy in infectious disease applications.

Direct peers

• Aligos Therapeutics: Aligos is developing antiviral therapeutics including interferon-pathway approaches for chronic viral diseases and respiratory infections. Comparable host-directed antiviral strategy; additionally, Ness scientific advisor Lawrence Blatt is CEO & Director at Aligos, indicating direct strategic linkage.
• SaNOtize Research: SaNOtize developed NONS, a nitric oxide nasal spray approved/authorized in multiple markets for upper respiratory virus protection. Closest direct comparator to N001 given similar intranasal self-administered prophylactic positioning.
• ENA Respiratory: ENA Respiratory is developing INNA-051, a broad-spectrum innate immune priming intranasal spray for respiratory virus protection. Directly comparable host-directed, virus-agnostic intranasal mechanism targeting the same first-contact window as N001.

Others

• Cobra Biologics (Charles River Laboratories): Cobra Biologics, now part of Charles River, provides contract development and manufacturing services for biologic and viral vector vaccines including intranasal delivery platforms. Relevant as a potential manufacturing partner given Ness's biologics CMC needs.

Market position

Weaknesses4 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/ness-therapeutics

Revenue estimate

Valuation estimate

Number of profiles

Profiles11 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Ness Therapeutics